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Abstract
Summary Regional variation in procedure use often reflects the uncertainty about the risks and benefit of procedures. In
Switzerland, regional variation in vertebroplasty and balloon kyphoplasty rates was high, although the variation declined between
2013 and 2018. Substantial parts of the variation remained unexplained, and likely signal unequal access and differing physician
opinion.
Purpose To assess trends and regional variation in percutaneous vertebroplasty (VP) and balloon kyphoplasty (BKP) use across
Switzerland.
Methods We conducted a population-based analysis using patient discharge data from all Swiss acute care hospitals for 2013–
2018.We calculated age/sex-standardizedmean procedure rates andmeasures of variation across VP/BKP-specific hospital areas
(HSAs). We assessed the influence of potential determinants of variation using multilevel regression models with incremental
adjustment for demographics, cultural/socioeconomic, health, and supply factors.
Results We analyzed 7855 discharges with VP/BKP from 31 HSAs. The mean age/sex-standardized procedure rate increased
from 16 to 20/100,000 persons from 2013 to 2018. While the variation in procedure rates across HSAs declined, the overall
variation remained high (systematic component of variation from 56.8 to 6.9 from 2013 to 2018). Determinants explained 52% of
the variation.
Conclusions VP/BKP procedure rates increased and regional variation across Switzerland declined but remained at a high level.
A substantial part of the regional variation remained unexplained by potential determinants of variation.
Keywords Balloon kyphoplasty . Geographical variation . Percutaneous vertebroplasty . Small area variation analysis .
Switzerland . Vertebral augmentation procedures
Introduction
Percutaneous vertebroplasty (VP) and balloon kyphoplasty
(BKP) are elective procedures used for the treatment of oste-
oporotic vertebral fractures. VP was first described in 1987 for
the treatment of vertebral angioma [1]. Later, BKP, a modified
VP technique that uses a balloon to erect the fractured verte-
bral body prior to the injection of bone cement, was intro-
duced in 1998 [2]. After small-sized, uncontrolled trials
showed substantial pain relief and few adverse events [3–5],
the procedures rapidly gained ground in clinical practice for
the treatment of osteoporotic vertebral fractures.
The evidence and recommendations for use of these proce-
dures have evolved over time. Two high-quality randomized
controlled trials (RCT) in 2009 showed no beneficial effect of
VP compared to a sham procedure [6, 7]. Thereafter, the
American Academy of Orthopaedic Surgeons (AAOS) rec-
ommended against the use of VP in the treatment of
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symptomatic osteoporotic spinal compression fractures [8],
and the procedure rates declined by 62% in the USA until
2015 [9, 10]. Other professional societies, however, still rec-
ommended VP in patients with painful osteoporotic vertebral
fractures refractory to medical therapy [11–14]. Two subse-
quent RCTs in patients with vertebral fractures of less than 6
weeks duration demonstrated more effective pain reduction
after VP compared to a sham procedure [15, 16]. However,
the VERTOS IV trial in 2018 showed no benefit of VP over a
sham intervention [17], and a large meta-analysis in 2018
found no clinically relevant benefit of VP over sham proce-
dures, with no difference based on duration of pain [18].
For BKP, recommendations were based on RCTs that
showed greater pain reduction for BKP compared to conser-
vative treatment [19–22], and improved correction of fracture-
related kyphosis and a lower rate of cement leakage in BKP
compared to VP [23, 24]. Despite the lack of sham procedure
controlled trials, US and European guidelines both recom-
mend the use of BKP for highly selected patients [8, 25]. As
a consequence, BKP rates gradually increased from 2010 to
2015 [9, 26, 27].
It is ultimately unclear who will benefit from VP or BKP
and the use of both procedures remain controversial [18].
While VP or BKP may lead to faster pain reduction and
shorter hospital stay in selected patients, potential adverse
events need to be considered. Leakage of bone cement is
frequent (69% of VPs) and may result in myelopathy with
need of surgical decompression (0.3% of patients with VP)
[28]. Other rare but potentially life-threatening complications
include cardiac or pulmonary cement embolism (3.9% and
3.5%, respectively [29]) as well as surgical site infections
(0.4% [30]). There is an ongoing controversy on whether
VP or BKP increases the risk of fractures of adjacent vertebra
[31, 32].
In controversial procedures, such as VP/BKP, geographical
variation may signal differing physician opinions more than
differing medical need or patient preferences [33–35]. In
Switzerland, guidelines recommend against the routine use of
VP/BKP [11], and very wide variations in procedure rates
across hospital service areas (HSAs) were observed between
2012 and 2013. [36]. Little is known about other potential
determinants of the observed variation and whether these var-
iations remain today. The aim of this study was to assess trends
and regional variation in VP/BKP between 2013 and 2018 and
examine potential determinants of the observed variation.
Methods
Data sources
We conducted a population-based, small area analysis based
on routinely collected patient discharge data from all Swiss
acute care hospitals for calendar years 2013 to 2018. The
methods have been described previously in detail [36, 37].
Briefly, all Swiss hospitals are legally obligated to provide
an anonymized, standardized dataset for each discharge to
the Swiss Federal Statistical Office (SFSO). These data are
centrally stored in the Swiss Hospital Discharge Masterfile.
Recorded variables include age, sex, nationality, insurance
status, type of admission (emergency vs. elective), up to 100
procedure codes based on the Swiss Classification of
Operations (CHOP, an adaptation of the U.S. ICD-9-CM vol-
ume 3 procedure classification), and diagnostic codes based
on the International Classification of Diseases, 10th revision,
German Modification (ICD-10-GM) [38]. Furthermore, the
patient’s area of residence and the location of the hospital
within one of 705 Swiss administrative (MedStat) regions
based on aggregated ZIP codes are recorded [39]. The SFSO
reviews data integrity and completeness by means of a specif-
ically designed software [40]. Since 2012, the Swiss Hospital
Discharge Masterfile covers 100% of discharges, and data
completeness for CHOP codes used in this analysis was high
[41].
We used Swiss National Cohort data [42] from 2014 to
determine the language region (Swiss German, Romance
[Italian or French]), and data from the SFSO to determine
the population density for each MedStat region. We used the
average Swiss Socioeconomic Position (SSEP, version 2) as a
measure of socioeconomic status. The SSEP version 2 was
derived using 2012–2015 Swiss structural surveys data to rank
Swiss neighborhoods based on four domains (median rent/m2,
proportion of households with a person with no/low educa-
tion, proportion with a person inmanual/unskilled occupation,
andmean crowding, all on the neighborhood level). The SSEP
varies between zero (lowest) and 100 (highest) and correlates
well with mortality [43]. We further obtained the density of
orthopedic surgeons and radiologists per MedStat region for
calendar year 2014 from the registry of physicians affiliated
with the Swiss Medical Association (FMH) (orthopedic sur-
geons do the majority of BKP and radiologists do the majority
of VP procedures in Switzerland). According to the Swiss
Human Research Act, this study was exempted from ethics
committee approval, because it was based on anonymized
administrative data only.
Derivation of VP/BKP-specific hospital service areas
Although Swiss hospital care is primarily organized based on
26 geographic regions (the cantons), patients may utilize hos-
pital services outside their canton of residence. Hence, the
cantons are not suitable units to compare regional variation
of VP/BKP utilization, because procedure rates may be
skewed. We therefore generated reproducible HSAs by a fully
automated method using all patients’ discharge data from cal-
endar years 2013–2016, which has been previously described
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in detail [44, 45]. Briefly, in a first step, we identified
4,105,885 discharges of patients aged ≥18 years living in
Switzerland from 155 Swiss acute care hospitals for calendar
years 2013–2016. Across the 705 Swiss administrative
(MedStat) regions, we identified regions that contain one or
several hospitals as potential HSAs. Starting from these po-
tential HSAs, in a centrifugal stepwise approach, we identified
the geographically neighboring MedStat regions and merged
them with the HSA if the majority of its residents were
discharged from hospitals located in the specific HSA (plural-
ity rule) [46]. HSAs with <50% of the patients being treated
within the same HSA or <10 discharges overall were merged
with the neighboring HSA which received most discharges
until >50% and ≥10 discharges occurred within each HSA.
This process yielded 63 general HSAs.
In a second step, we identified patient discharges with spe-
cific CHOP codes for VP (codes 81.65.x) and BKP (codes
81.66.x) from all Swiss acute care hospitals for calendar years
2013–2018 using the Swiss Hospital DischargeMasterfile. As
VP and BKP are not performed in every hospital, we analyzed
patient flows for VP/BKP. Using the procedure described
above, HSAs were further aggregated into 31 VP/BKP-
specific HSAs. We then drew visual maps of the 31 final
HSAs using Geographical Information System (GIS)–com-
patible vector files.
Study population
We identified 18,522 discharges with specific CHOP codes
for VP or BKP during calendar years 2013–2018
(Supplementary Fig 2). After delineating the HSAs, we ex-
cluded all discharges related to emergencies (n = 7169), and
discharges with concomitant ICD-10-GM codes for accidents,
intentional self-harm, or assault (ICD-10 GM code groups X,
Y, Z; n = 2125). Because pathologic fractures due to vertebral
metastases or multiple myeloma may be appropriate indica-
tions for VP/BKP [47, 48], we excluded 1373 discharges with
ICD-10-GM codes for metastatic cancer or multiple myeloma
(ICD-10 codes C77.x–C80.x, C90.0-, M49.5- and M82.0),
leaving a final study population of 7855 patient discharges
with elective VP or BKP. Discharges with both procedures
were assigned to the BKP group.
Measures of variation
We calculated unadjusted and age- and sex-standardized VP/
BKP procedure rates per 100,000 persons for each HSA using
procedure counts and 2013–2018 census data for the adult
Swiss population [49]. We used direct standardization with
age bands of 18–49, 50–54, 55–59, 60–64, (...), 75–79, and
≥80 years. To examine the variation in procedure rates across
the procedure-specific HSAs, we calculated three different
measures of variation: We determined the extremal quotient
(EQ), which is the highest, divided by the lowest procedure
rate. While this is an intuitive measure of variation, it is prone
to distortion by extreme values [34]. We further calculated the
coefficient of variation (CV), which is the ratio of the standard
deviation of the procedure rates to the mean rate, and the
systematic component of variation (SCV) [34, 50, 51].
Although less intuitive, the SCV represents the non-random
part of the variation in procedure rates while reducing the
effect of extreme values [34, 50, 52]. It has been suggested
that SCVs >5 are largely due to differences in practice styles
or medical discretion and an SCV of >10 is considered indic-
ative of a very high variation [34, 52].
Determinants of variation
Differences in illness incidences and socioeconomic factors
are possible causes of variation [34]. Therefore, we explored
the following domains, which potentially influence procedure
rates: demographics (patients’ age), cultural and socioeco-
nomic factors (language region, population density, socioeco-
nomic status, insurance class, citizenship), population health
(burden of disease), and supply factors (physician density).
The language spoken by the majority of people living in a
HSA was used to classify each HSA as either Swiss German
or Romance (French/Italian) language region as a proxy for
culture. We used population density as a proxy for the type of
neighborhood a resident lives in (e.g., countryside areas have
low density, cities generally have higher density). The socio-
economic status of each HSA was measured using the mean
value of the SSEP of persons within an HSA. The percentage
of discharges with (semi-)private insurance status and Swiss
citizenship was used as an additional measure of the socioeco-
nomic status of each HSA. As a proxy for the population
burden of disease, we calculated age-standardized incidence
rates of hip fractures (ICD 10 codes S720 - 22), colon (ICD 10
codes C18/19 and CHOP codes 457- 58 or 446) or lung cancer
(ICD 10 codes C34 and CHOP codes 323 -26 or 329) treated
surgically, acute myocardial infarctions (ICD 10 codes I21),
or strokes (ICD 10 codes I63/64) for each HSA, as differences
in these disease rates are likely to reflect true regional differ-
ences in burden of disease rather than differences in coding
intensity or supply factors [53, 54]. The density of orthopedic
surgeons and radiologists was used as a supply measure.
Statistical analyses
We used incrementally adjusted multilevel Poisson regression
with a log link tomodel the procedure rates in each HSA using
age bands of 18–49, 50–54, 55–59, 60–64, (...), 75–79, and
≥80 years. HSA was included as a random intercept in all
models. In a stepwise approach, model 1 adjusted only for
the calendar year of the procedure, model 2 was additionally
adjusted for demographics, model 3 added socioeconomic and
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cultural factors, model 4 regional health, and model 5 supply
factors. Variables included in the model were chosen a priori
as we expected them to influence the rates. We used the
models in three ways: (1) to assess to what extent VP/BKP
rates in Switzerland can be explained by explanatory factors,
(2) to assess the variance explained by the domains defined
previously, and (3) to calculate intervention rates per 100,000
persons per HSA. For the first, we expressed the effect of
explanatory factors on VP/BKP rates as incidence rate ratios
(IRRs), defined as the VP/BKP rate in the defined category
(e.g., Romance language region) relative to the estimated VP/
BKP rate in the reference category (e.g., Swiss German lan-
guage region). For the second use, we determined the percent-
age reduction in procedure variation across the 31 HSAs by
examining the variance of the random intercept relative to
model 1. We considered the residual, unexplained variation
of the fully adjusted model a proxy for unwarranted variation.
For the third use, we used the models to predict rates in each
HSA. Sets of models were created for overall rates as well as
for VP and BKP separately. We further assessed remaining
variation in procedure rates across HSAs after full adjustment
(model 5) using funnel plots. We plotted procedure rates
against population size for each HSA. The mean procedure
rates and the control limits of 2 and 3 standard deviations
above and below the mean (95% and 99.8% confidence inter-
vals), respectively, were calculated for all possible values for
population size and used to create the funnel plot based on
exact Poisson confidence intervals [55]. Statistical modeling
was performed using Stata version 15.1 (StataCorp, College
Station, TX, USA). HSAs were delineated and maps drawn
using the R statistical software version 3.6.1 [56].
Results
Characteristics of VP/BKP-specific HSAs and the study
population
For the 31 VP/BKP-specific HSAs delineated, the median
population size per HSA was 785,112 persons (interquartile
range [IQR] 355,009–2,456,318), with a median population
density of 1580 persons per km2 (IQR 369–2712), a mean
SSEP of 56 points (standard deviation [SD] 5.4), and amedian
density of orthopedic surgeons and radiologists of 21 per
10,000 persons (IQR 13–27). Overall, 23 HSAs were located
in the Swiss German and 8 in Romance (4 French and 4
Italian) language regions.
Of the 7855 patients discharged with VP/BKP, 6110 (78%)
underwent VP and 2413 (31%) BKP procedures (668 (9%)
had both). The majority of patients were female (74%), ≥70
years old (72%), and Swiss citizens (92%, Table 1).
Variation in procedure rates across HSAs
Across 2013–2018, the mean age/sex-standardized VP/BKP rate
was 18 (range 2–35) per 100,000 persons, ranging across years
from 16 per 100,000 persons per year in 2014 to 20 per 100,000
persons per year in 2018.After full adjustment for demographics,
Table 1 Characteristics of patients receiving vertebroplasty (VP) and
balloon kyphoplasty (BKP) in Switzerland 2013–2018
Total VP group BKP group
(N = 7855) (N = 5442) (N = 2413)
n (%)
Case year
2013 1166 (15) 823 (15) 343 (14)
2014 1141 (15) 756 (14) 385 (16)
2015 1248 (16) 890 (16) 358 (15)
2016 1387 (18) 986 (18) 401 (17)
2017 1376 (18) 937 (17) 439 (18)
2018 1537 (20) 1050 (19) 487 (20)
Female sex 5804 (74) 4046 (74) 1758 (73)
Age
18–49 169 (2) 81 (2) 88 (4)
50–54 169 (2) 106 (2) 63 (3)
55–59 363 (5) 234 (2) 129 (5)
60–64 556 (7) 363 (7) 193 (8)
65–69 909 (12) 663 (12) 246 (10)
70–74 1430 (18) 1022 (19) 408 (17)
75–79 1777 (23) 1247 (23) 530 (22)
≥80 2482 (32) 1726 (32) 756 (31)
Insurance class
General 4425 (56) 2979 (55) 1446 (60)
(Semi-)Private 3430 (44) 2463 (45) 967 (40)
Citizenship
Swiss 7247 (92) 5062 (93) 2185 (91)
Non-Swiss 608 (8) 380 (7) 228 (9)
Intervention
VP procedures 6110 (78) * 5442 (100) 668 (28)
1 vertebral body 2441 (31) 2159 (40) 282 (12)
2 vertebral bodies 1761 (22) 1490 (27) 271 (11)
3 vertebral bodies 1080 (14) 1014 (19) 66 (3)
≥4 vertebral bodies 887 (11) 827 (15) 60 (2)
Not specified 38 (0) 38 (1) 0 (0)
BKP procedures 2413 (31) 0 (0) 2413 (100)
1 vertebral body 1820 (23) 0 (0) 1820 (75)
2 vertebral bodies 401 (5) 0 (0) 401 (17)
3 vertebral bodies 144 (2) 0 (0) 144 (6)
≥4 vertebral bodies 60 (1) 0 (0) 60 (2)
Not specified 3 (0) 0 (0) 2 (0)
*The number of overall VP procedures exceeded the number of dis-
charges in the VP group, as 668 patients in the BKP group received both
BKP and VP during the same hospital stay
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cultural, socioeconomic, health, and supply factors, and combin-
ing all years, the predicted VP/BKP rates varied between 4 and
40 per 100,000 persons per year across HSAs (Supplementary
Fig. 1). For individual procedures, the mean age/sex-
standardized VP rate was 12 (range 0–30 across HSAs) per
100,000 persons and the mean age/sex-standardized BKP rate
was 6 (range 1–18 across HSAs) per 100,000 persons.
The overall EQ was 17.4, the CV 0.5, and the SCV 17.7,
indicating very high variation across HSAs (Table 2). Both
VP (EQ 73.1, CV 0.7, SCV 38.6) and BKP (EQ 28.9, CV 0.7,
SCV 45.8) also showed very high regional variation. Between
2013 and 2018, the variation across HSAs decreased for both
VP and BKP (by all measures, seen in Table 2), while the
median procedure rates increased from 7 to 11 per 100,000
persons for VP and from 5 to 6 per 100,000 persons for BKP
(Fig. 1). Despite the decrease in variation, it remained high in
2018 for both VP and BKP (e.g., SCV >6 for combined pro-
cedures and SCV >20 for individual procedures (Table 2).
Determinants of variation in procedure rates
Between 2013 and 2018, overall VP/BKP rates increased by
7% per year (IRR 1.07, 95% confidence interval [CI] 1.05–
1.10) in the fully adjusted model (Table 3). VP/BKP rates
were highest in patients aged 75–79 years (IRR 23.37, CI
19.96–27.36 compared to patients aged 50–54 years). The rate
in females was more than twice the rate in male patients (IRR
2.25, CI 2.14–2.36). Compared to the year-adjusted model
(model 1), additional adjustment for demographic, cultural,
and socioeconomic factors (model 3) explained 44.5% of the
variation in procedure rates. After additional adjustment for
health and supply factors (model 5), 51.6% of the variation in
procedure rates was explained (i.e., 48.4% of the variation
remained unexplained) (Table 3).
The variance remaining in fully adjusted models was larger
for the individual procedures (Supplementary Table 1). For
VP and BKP, the remaining variance was 82.4% and 80.9%,
respectively. The relationships between variables of interest
and procedure rates were qualitatively similar for the individ-
ual procedures, with year, age, female sex associated with
higher procedure rates (Supplementary Table 1)
When plotting the procedure rates against population size,
several HSAs had procedure rates above or below the outer
control limits of 3 standard deviations, indicating unusually
high (HSAs 4, 6, and 8, around Bern) or low procedure rates
(HSA 1 (Geneva) and 7 (Basel)) (Supplementary Fig. 3).
HSAs with high procedure rates all lay in the greater Bern
Table 2 Measures of variation in age/sex-standardized vertebroplasty
and balloon kyphoplasty procedure rates across Swiss HSAs through the
years 2013–2018
Overall 2013 2014 2015 2016 2017 2018
All procedures (vertebroplasty and kyphoplasty)
EQ 17.40 10.28 6.18 7.07 6.76 6.38 4.92
CV 0.47 0.60 0.50 0.46 0.46 0.39 0.31
SCV 17.74 56.75 29.45 21.51 20.85 14.07 6.93
N * 31 21 21 23 23 23 24
Vertebroplasty
EQ 73.14 12.80 7.79 9.66 8.35 11.02 6.64
CV 0.72 0.75 0.68 0.58 0.60 0.58 0.48
SCV 38.62 126.83 85.43 54.86 46.59 35.54 20.06
N * 31 16 15 18 19 20 20
Balloon kyphoplasty
EQ 28.92 9.09 9.09 7.05 6.48 10.25 6.63
CV 0.65 0.73 0.51 0.54 0.47 0.61 0.49
SCV 45.75 172.02 98.44 48.48 48.24 104.55 53.83
N * 31 13 14 11 11 12 14
Abbreviations: EQ, extremal quotient; CV, coefficient of variation; SCV,
systematic component of variation; N, number of HSAs included in the
analysis
*The number of HSAs included in the analysis varies from year to year,
as HSAs with less than 10 interventions in a given year were removed
Fig. 1 Age- and sex-standardized HSA vertebroplasty (A) and balloon
kyphoplasty (B) rates (per 100,000 persons per year) through time. Each
violin illustrates the procedure rates in a given year. Wider sections of the
violin represent higher amounts of HSAswith a given procedure rate. The
white dots inside the violins indicate median procedure rates, the black
bars the interquartile ranges, and the black lines the lower/upper adjacent
values. HSAs with fewer than 10 interventions in a given year were
removed (i.e., the number of HSAs in each year changes. Consult
Table 2 for the exact numbers)
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area, and tended to have a lower population and specialty-
physician density compared to the HSAs with low procedure
rates (Supplementary Table 2).
Discussion
In this analysis of all hospital discharges in Switzerland from
2013 to 2018, we found substantial regional variation in VP/
BKP procedure rates, although the variation decreased over
time. During the observed time period, while regional varia-
tion decreased, the procedure rates increased by 57% for VP
and by 20% for BKP, respectively.We identified age, sex, and
health and supply factors as statistically significant determi-
nants of variation in VP/BKP rates. However, a large amount
of variation remained unexplained by our models.
The variation in VP/BKP rates across HSAs steadily de-
clined over time, but remained high by 2018. While previous
studies also demonstrated substantial regional variation in VP/
BKP rates across Switzerland [36] and across the USA [57-
59], to our knowledge, our report is the first to specifically
evaluate the time trend of the variation.We can only speculate
on explanations for the observed trend. Between 2010 and
2016, many un-blinded trials that compared VP or BKP to
Table 3 Incidence rate ratios (IRR) of VP/BKP and remaining variance after incremental adjustment for determinants of variation across 31 Swiss
HSAs 2013–2018
Model 1* Model 2† Model 3‡ Model 4§ Model 5¶
Incidence rate ratio (95%CI)#
Year (per year) 1.05
(1.04–1.06)
1.04 (1.03–1.05) 1.04 (1.03–1.06) 1.08 (1.05–1.10) 1.07 (1.05–1.10)
Age 18–49 0.18 (0.15–0.22) 0.18 (0.15–0.22) 0.18 (0.15–0.22) 0.18 (0.15–0.22)
50–54 Reference Reference Reference Reference
55–59 2.46 (2.05–2.95) 2.46 (2.05–2.95) 2.46 (2.05–2.95) 2.46 (2.05–2.95)
60–64 4.44 (3.73–5.27) 4.43 (3.73–5.27) 4.44 (3.73–5.27) 4.44 (3.73–5.27)
65–69 8.00 (6.79–9.42) 8.00 (6.79–9.42) 8.00 (6.79–9.43) 8.00 (6.79–9.43)
70–74 14.36 (12.25–16.84) 14.36 (12.25–16.85) 14.37 (12.25–16.85) 14.37 (12.25–16.85)
75–79 23.36 (19.95–27.36) 23.36 (19.95–27.36) 23.36 (19.95–27.36) 23.37 (19.96–27.36)
≥80 20.61 (17.63–24.09) 20.61 (17.63–24.09) 20.61 (17.63–24.09) 20.62 (17.64–24.10)
Sex Male Reference Reference Reference Reference




Romance 0.66 (0.46–0.96) 0.67 (0.45–1.00) 0.74 (0.52–1.05)
Population density (per 100/km2) 1.01 (0.99–1.03) 1.00 (0.98–1.02) 1.01 (0.99–1.03)
Mean SSEP (per 10 points) 0.96 (0.93–1.00) 0.97 (0.93–1.01) 0.98 (0.94–1.01)
(Semi)private insurance (per 10%
change)
1.02 (0.78–1.34) 1.04 (0.78–1.39) 1.00 (0.77–1.30)
Swiss citizenship (per 10% change) 1.23 (1.02–1.48) 1.20 (0.99–1.46) 1.15 (0.96–1.39)
Burden of disease (per 1/10,000)** 0.88 (0.83–0.94) 0.89 (0.84–0.95)
Density of specialists (per 1/10,000)†† 0.98 (0.97–0.99)
Remaining variance from model 1 (%) ‡‡ 99.0 55.5 66.1 48.4
Abbreviations:HSA, hospital service area;CI, confidence interval; SSEP, Swiss neighborhood index of socioeconomic position. Results in bold indicate
a statistically significant effect
*Adjusted for year
†Additionally adjusted for age and sex
‡Additionally adjusted for language region and (semi)private insurance status
§Additionally adjusted for burden of disease
¶Additionally adjusted for density of orthopedic surgeons and radiologists
#VP/BKP rate in the defined category relative to the VP/BKP rate in the reference category. For instance, an incidence rate ratio of 2.25 indicates a 125%
higher VP/BKP rate in women than in men
**Burden of disease represents the sum of age-standardized incidence rates for the following comorbidities: hip fracture, colon or lung cancer treated
surgically, acute myocardial infarction, and stroke. The IRR is the increase (decrease) in procedure rates when the regional burden of disease increases by
1 comorbidity per 1000 person
††Density of orthopedic surgeons and radiologists. The IRR is the increase (decrease) in procedure rates when the number of orthopedic surgeons
increases by 10 orthopedic surgeons
‡‡Expresses the variance in VP/BKP rates from the average national rate
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conservative treatment demonstrated a statistically significant
faster and/or greater pain reduction following an intervention
[19, 22, 60-63]. Furthermore, the VAPOUR and VOPE trials
showed better outcomes after VP in patients with acute oste-
oporotic vertebral fractures in 2016 [15, 16]. The results of
these studies, together with the availability of an increasing
number of international guidelines [12-14, 25, 64], might have
convinced some physicians to use VP/BKP in patients with
painful vertebral fractures refractory to medical therapy, even
though the topic remained controversial. A large meta-
analysis eventually showed no clinically relevant benefits of
VP in 2018 [18] and, in early 2019, the American Society for
Bone and Mineral Research (ASBMR) recommended against
routine use of vertebral augmentation for osteoporotic verte-
bral fractures [65].
Large amounts of variation in procedure rates across
Switzerland is not an isolated phenomenon for VP/BKP and
has also been reported for other orthopedic interventions (e.g.,
SCV >33 for shoulder arthroscopy [66]) or hysterectomy
(e.g., SCV >16 for abdominal hysterectomy [37]). The similar
levels of regional variation may signal unequal access to sur-
gery and widely differing physician’s opinions regarding sur-
gical interventions across the country. It has previously been
demonstrated that variation across geographically close small
areas is intimately related to individual physicians’ practice
style rather than to patient need or preferences [34].
While the regional variation decreased, we found a steady
increase in both VP (+57%) and BKP rates (+20%) between
2013 and 2018. This increase is despite an unchanged recom-
mendation from the Swiss medical board since 2011 against
use of VK/BKP beyond trials. In comparison, in the USA,
there was a substantial decrease in both VP and (less distinct)
BKP rates in 2009 [58] after the publication of the first nega-
tive sham procedure controlled trials [6, 7], and the VP rates
continued to decline between 2010 and 2018 while the BKP
rates rose again during the mentioned time period [10]. In
Germany and South Korea, VP/BKP rates also increased be-
tween 2005–2014 and 2012–2016, respectively [67, 68].
Several measured variables were associated with rates of
VP and BKP in our analysis. Higher age and female sex are
well-known risk factors for osteoporosis and the association
with higher VP/BKP rates in this population group is evident.
Less intuitively, we found an association between a higher
density of specialty physicians and lower procedure rates.
Previous studies demonstrated that higher rates of surgical
interventions were not explained by differences in the number
of surgeons within a specific area, but rather by enthusiasm for
that procedure among a small number of high-volume sur-
geons in that region [69, 70]. Due to our study design, we
were not able to assess surgeons’ enthusiasm for VP/BKP.
Furthermore, we used the density of all registered radiologists
and orthopedic surgeons (not only physicians performing VP/
BKP) as a proxy for supply factors. Further studies to
investigate physicians’ enthusiasm for VP/BKP might offer
valuable clues to explaining regional variation in the proce-
dure rates.
In HSAs with a lower burden of disease, we observed
higher VP/BKP rates. One explanation might be that healthier
patients usually are physically more active and thus are more
likely to demand a surgical intervention for treatment of a
vertebral fracture, hoping quickly to regain their active life-
style. In previous studies, varying associations between co-
morbidities and VP/BKP rates were found [71-73]. It has to
be noted that our study assessed burden of disease at a regional
level, not on patient level.
In our analysis, nearly half of the regional variation in VP/
BKP rates remained unexplained after adjustment for potential
explanatory factors, highlighting clinical uncertainty about
their use. VP and BKP remain controversial and it is not pos-
sible to determine the appropriate rate of such procedures, but
the high regional variation indicates unequal access to the
procedures across Switzerland. In practice, this may suggest
overuse and unnecessarily putting patients at risk for adverse
events in some regions, while patients in other regions might
be left at risk for prolonged or more severe pain and disability.
Better understanding is needed of how and why physicians
and patients make these decisions about procedure use.
Our study has several limitations. We used administrative
discharge data, and there might be errors due to inaccurate
coding of main or comorbid diagnoses and procedures.
Furthermore, data about the indications for procedures or
about severity and age of the vertebral fractures were not
available. Neither could we explore other potential determi-
nants of regional variation, such as prevalence of osteoporosis,
differences in physicians’ and patients’ preferences, or train-
ing of local physicians. Behavior/procedure rates of individual
service providers, be they hospitals or physicians, could not be
analyzed due to data protection issues, but will be important to
assess in future work. We found associations between VP/
BKP rates and several determinants on a regional level, but
cannot infer causality. Furthermore, for the determinants of
variation of interest, we used data of single calendar year
(e.g., density of specialty physicians in 2014) and could not
account for potential annual variation in these variables. Such
covariates are also aggregated from finer scale measurements,
which averages away some variation. In addition, our HSAs
are of different sizes, and the regions they contain are not of
uniform size (e.g., a relatively small HSA may be composed
of a few large MedStat regions while a large HSA may be
composed of many small and large MedStat regions). This
effectively results in different sub-regions receiving different
weights when considering the effects of the covariates if there
are particularly high or low values in some sub-regions. As
some MedStat regions (the smallest geographical unit of our
analysis) contain several hospitals, we could not assess the
procedure rates of and variation between individual hospitals
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in individual regions. Finally, because of lacking national data
on outpatient procedures, we examined inpatient VP and BKP
only. However, according to a major Swiss health insurer, the
proportion of outpatient VP and BKP is very small (<10%).
In conclusion, we found a declining, but still high, level of
variation in VP/BKP rates across Swiss HSAs between 2013
and 2018. Procedure rates during this time increased steadily.
A substantial part of the regional variation remained unex-
plained by differences in demographic, cultural, socioeco-
nomic, health, and supply factors.
Supplementary Information The online version contains supplementary
material available at https://doi.org/10.1007/s00198-021-06026-x.
Funding Open Access funding provided by Universität Bern. This re-
search project was supported by the National Research Program 74,
Grant number SNF 407440_167339, the Health Services Research
funding program of the Gottfried and Julia Bangerter-Rhyner-Stiftung,
and the Swiss Society of General Internal Medicine Foundation.
Data availability It is not possible to share the individual level data for
sake of confidentiality. However, we have obtained permission to share
the aggregated data used in the models. We will upload the data to the
University of Bern’s repository (DOI will be provided) once the manu-
script is accepted for publication and no additional changes are foreseen.
As such, the data to run the models will be made available. Due to privacy
laws in Switzerland, we are unable to share the data to reproduce tables
with intervention and demographics. Requests for such data must be
made to the SFSO: Swiss Federal Statistical Office (SFSO) Sektion
Gesundheitsversorgung, Espace de l’Europe 10, CH-2010 Neuchâtel,
Switzerland, Phone: +41 58 463 67 00, Email: gesundheit@bfs.admin.ch.
Declarations
Ethics approval According to the Swiss Human Research Act, this
study was exempted from ethics committee approval, because it was
based on anonymized administrative data only.
Consent to participate Not applicable.
Consent for publication Not applicable.
Conflicts of interest The authors have declared that no competing inter-
ests exist. A. G. Haynes is affiliated with CTU Bern, University of Bern,
which has a staff policy of not accepting honoraria or consultancy fees.
However, CTUBern is involved in design, conduct, or analysis of clinical
studies funded by not-for-profit and for-profit organizations. In particular,
pharmaceutical and medical device companies provide direct funding to




1. Galibert P, Deramond H, Rosat P, Le Gars D (1987) Preliminary
note on the treatment of vertebral angioma by percutaneous acrylic
vertebroplasty. Neurochirurgie. 33(2):166–168
2. Kushchayev SV,Wiener PC, TeytelboymOM, Arrington JA, Khan
M, Preul MC (2019) Percutaneous vertebroplasty: a history of pro-
cedure, technology, culture, specialty, and economics.
Neuroimaging Clin N Am 29(4):481–494
3. Voormolen MH, Mali WP, Lohle PN, Fransen H, Lampmann LE,
van der Graaf Y, Juttmann JR, Jansssens X, Verhaar HJ (2007)
Percutaneous vertebroplasty compared with optimal pain medica-
tion treatment: short-term clinical outcome of patients with sub-
acute or chronic painful osteoporotic vertebral compression frac-
tures. The VERTOS study. AJNR Am J Neuroradiol 28(3):555–
560
4. Alvarez L, Alcaraz M, Perez-Higueras A et al (2006) Percutaneous
vertebroplasty: functional improvement in patients with osteoporot-
ic compression fractures. Spine (Phila Pa 1976) 31(10):1113–1118
5. Diamond TH, Champion B, Clark WA (2003) Management of
acute osteoporotic vertebral fractures: a nonrandomized trial com-
paring percutaneous vertebroplasty with conservative therapy. Am
J Med 114(4):257–265
6. Buchbinder R, Osborne RH, Ebeling PR, Wark JD, Mitchell P,
Wriedt C, Graves S, Staples MP, Murphy B (2009) A randomized
trial of vertebroplasty for painful osteoporotic vertebral fractures. N
Engl J Med 361(6):557–568
7. Kallmes DF, Comstock BA, Heagerty PJ, Turner JA, Wilson DJ,
Diamond TH, Edwards R, Gray LA, Stout L, Owen S,
Hollingworth W, Ghdoke B, Annesley-Williams DJ, Ralston SH,
Jarvik JG (2009) A randomized trial of vertebroplasty for osteopo-
rotic spinal fractures. N Engl J Med 361(6):569–579
8. Esses SI, McGuire R, Jenkins J, Finkelstein J, Woodard E, Watters
WC III, Goldberg MJ, Keith M, Turkelson CM, Wies JL, Sluka P,
Boyer KM, Hitchcock K (2011) The treatment of symptomatic
osteoporotic spinal compression fractures. J Am Acad Orthop
Surg 19(3):176–182
9. Rabei R, Patel K, Ginsburg M, Patel MV, Turba UC, Arslan B,
Ahmed O (2019) Percutaneous vertebral augmentation for vertebral
compression fractures: national trends in the medicare population
(2005-2015). Spine (Phila Pa 1976) 44(2):123–133
10. Lindquester WS, Warhadpande S, Dhangana R (2020) Trends of
utilization and physician payments for vertebroplasty and
kyphoplasty procedures by physician specialty and practice setting:
2010 to 2018. Spine J 20(10):1659–1665
11. Swiss Medical Board. Vertebroplastie und Kyphoplastie bei
osteoporotischen Wirbelkörperfrakturen. [Internet]. 2011




12. National Institute for Health and Care Excellence. Percutaneous
vertebroplasty and percutaneous balloon kyphoplasty for treating
osteoporotic vertebral compression fractures. Technology appraisal
guidance. NICE guidance [Internet]. 2013 April 24 [cited 2020
March 31]. Available from: https://www.nice.org.uk/guidance/
ta279
13. Barr JD, Jensen ME, Hirsch JA et al (2014) Position statement on
percutaneous vertebral augmentation: a consensus statement devel-
oped by the Society of Interventional Radiology (SIR), American
Association of Neurological Surgeons (AANS) and the Congress of
Neurological Surgeons (CNS), American College of Radiology
(ACR), American Society of Neuroradiology (ASNR), American
Society of Spine Radiology (ASSR), Canadian Interventional
Radio logy Associa t ion (CIRA), and the Soc ie ty of
NeuroInterventional Surgery (SNIS). J Vasc Interv Radiol 25(2):
171–181
14. Chandra RV, Meyers PM, Hirsch JA, Abruzzo T, Eskey CJ,
Hussain MS, Lee SK, Narayanan S, Bulsara KR, Gandhi CD, Do
HM, Prestigiacomo CJ, Albuquerque FC, Frei D, Kelly ME, Mack
WJ, Pride GL, Jayaraman MV, on behalf of the Society of
Osteoporos Int
NeuroInterventional Surgery (2014) Vertebral augmentation: re-
port of the Standards and Guidelines Committee of the Society of
NeuroInterventional Surgery. J Neurointerv Surg 6(1):7–15
15. ClarkW, Bird P, Gonski P, Diamond TH, Smerdely P, McNeil HP,
Schlaphoff G, Bryant C, Barnes E, Gebski V (2016) Safety and
efficacy of vertebroplasty for acute painful osteoporotic fractures
(VAPOUR): a multicentre, randomised, double-blind, placebo-
controlled trial. Lancet 388(10052):1408–1416
16. Hansen EJ, Simony A, Rousing R, Carreon LY, Tropp H, Andersen
MØ (2017) Double blind placebo-controlled trial of percutaneous
vertebroplasty (VOPE). Global Spine Journal 6(1_suppl) s-0036-
1582763
17. Firanescu CE, de Vries J, Lodder P et al (2018) Vertebroplasty
versus sham procedure for painful acute osteoporotic vertebral
compression fractures (VERTOS IV): randomised sham controlled
clinical trial. BMJ. 361:k1551
18. Buchbinder R, Johnston RV, Rischin KJ et al (2018) Percutaneous
vertebroplasty for osteoporotic vertebral compression fracture.
Cochrane Database Syst Rev 4:CD006349
19. Farrokhi MR, Alibai E, Maghami Z (2011) Randomized controlled
trial of percutaneous vertebroplasty versus optimal medical man-
agement for the relief of pain and disability in acute osteoporotic
vertebral compression fractures. J Neurosurg Spine 14(5):561–569
20. Van Meirhaeghe J, Bastian L, Boonen S et al (2013) A randomized
trial of balloon kyphoplasty and nonsurgical management for
treating acute vertebral compression fractures: vertebral body ky-
phosis correction and surgical parameters. Spine (Phila Pa 1976)
38(12):971–983
21. Wardlaw D, Cummings SR, Van Meirhaeghe J et al (2009)
Efficacy and safety of balloon kyphoplasty compared with non-
surgical care for vertebral compression fracture (FREE): a
randomised controlled trial. Lancet. 373(9668):1016–1024
22. Boonen S, Van Meirhaeghe J, Bastian L et al (2011) Balloon
kyphoplasty for the treatment of acute vertebral compression frac-
tures: 2-year results from a randomized trial. J Bone Miner Res
26(7):1627–1637
23. Vogl TJ, Pflugmacher R, Hierholzer J, Stender G, Gounis M,
Wakhloo A, Fiebig C, Hammerstingl R (2013) Cement directed
kyphoplasty reduces cement leakage as compared with
vertebroplasty: results of a controlled, randomized trial. Spine
(Phila Pa 1976) 38(20):1730–1736
24. Dohm M, Black CM, Dacre A, Tillman JB, Fueredi G (2014) in-
vestigators K. A randomized trial comparing balloon kyphoplasty
and vertebroplasty for vertebral compression fractures due to oste-
oporosis. AJNR Am J Neuroradiol 35(12):2227–2236
25. Tsoumakidou G, Too CW, Koch G, Caudrelier J, Cazzato RL,
Garnon J, Gangi A (2017) CIRSE guidelines on percutaneous ver-
tebral augmentation. Cardiovasc Intervent Radiol 40(3):331–342
26. Degnan AJ, Hemingway J, Hughes DR (2017) Medicare utilization
of vertebral augmentation 2001 to 2014: effects of randomized
clinical trials and guidelines on vertebroplasty and kyphoplasty. J
Am Coll Radiol 14(8):1001–1006
27. CoxM, Levin DC, Parker L, MorrisonW, Long S, Rao VM (2016)
Vertebral augmentation after recent randomized controlled trials: a
new rise in kyphoplasty Volumes. J Am Coll Radiol 13(1):28–32
28. Hsieh MK, Kao FC, Chiu PY, Chen LH, Yu CW, Niu CC, Lai PL,
Tsai TT (2019) Risk factors of neurological deficit and pulmonary
cement embolism after percutaneous vertebroplasty. J Orthop Surg
Res 14(1):406
29. Fadili Hassani S, Cormier E, Shotar E, Drir M, Spano JP, Morardet
L, Collet JP, Chiras J, Clarençon F (2019) Intracardiac cement
embolism during percutaneous vertebroplasty: incidence, risk fac-
tors and clinical management. Eur Radiol 29(2):663–673
30. Park JW, Park SM, Lee HJ, Lee CK, Chang BS, Kim H (2018)
Infection following percutaneous vertebral augmentation with
polymethylmethacrylate. Arch Osteoporos 13(1):47
31. Lou S, Shi X, Zhang X, Lyu H, Li Z, Wang Y (2019) Percutaneous
vertebroplasty versus non-operative treatment for osteoporotic ver-
tebral compression fractures: a meta-analysis of randomized con-
trolled trials. Osteoporos Int 30(12):2369–2380
32. Piazzolla A, Bizzoca D, Solarino G, Moretti L, Moretti B (2020)
Vertebral fragility fractures: clinical and radiological results of aug-
mentation and fixation-a systematic review of randomized con-
trolled clinical trials. Aging Clin Exp Res 32(7):1219–1232
33. Anthony DL, Herndon MB, Gallagher PM, Barnato AE, Bynum
JPW, Gottlieb DJ, Fisher ES, Skinner JS (2009) How much do
patients’ preferences contribute to resource use? Health Aff
(Millwood) 28(3):864–873
34. Appleby J, Raleigh V, Frosini F, Bevan G, Gao H, Lyscom T.
Variations in healthcare: the good, the bad and the inexplicable2011




35. Birkmeyer JD, Reames BN, McCulloch P, Carr AJ, Campbell WB,
Wennberg JE (2013) Understanding of regional variation in the use
of surgery. Lancet. 382(9898):1121–1129
36. Scheuter C, Wertli MM, Haynes AG, Panczak R, Chiolero A,
Perrier A, Rodondi N, Aujesky D (2018) Unwarranted regional
variation in vertebroplasty and kyphoplasty in Switzerland: a
population-based small area variation analysis. PLoS One 13(12):
e0208578
37. Stoller N, Wertli MM, Zaugg TM, Haynes AG, Chiolero A,
Rodondi N, Panczak R, Aujesky D (2020) Regional variation of
hysterectomy for benign uterine diseases in Switzerland. PLoSOne
15(5):e0233082
38. Swiss Federal Statistical Office (SFSO). Schweizerische
Operationsklassifikation (CHOP), ICD-9-CM, 3 Version 11.0,
Neuchâtel 2008. Available from: https://www.bfs.admin.ch/bfs/
de/home/statistiken/gesundheit/nomenklaturen/medkk/
instrumente-medizinische-kodierung.html
39. Swiss Federal Statistical Office (SFSO). Die Raumgliederungen der
Schweiz 2014 Available from: https://www.bfs.admin.ch/bfs/de/
home/grundlagen/raumgliederungen.html
40. Hasler S. Bundesamt für Statistik BFS, Plausibilisierungskonzept
der Medizinischen Statistik der Krankenhäuser. Version 5.0.8.1
2016 [2020/03/15]. Available from: http://www.freudiger.com/
download/mp5_konzept_D_20160122.pdf
41. Swiss Federal Statistical Office (SFSO). Medizinische Statistik der
Krankenhäuse r 2015. S tandard tabe l l en . Neuchâ te l ,




42. Egger M, Puhan M, Paccaud F, Künzli N, Oris M. Swiss National
Cohort 2014. Available from: https://www.swissnationalcohort.
ch/?id=2992
43. Panczak R, Galobardes B, Voorpostel M, Spoerri A, Zwahlen M,
Egger M, for the Swiss National Cohort and the Swiss Household
Panel (2012) A Swiss neighbourhood index of socioeconomic po-
sition: development and association with mortality. J Epidemiol
Community Health 66(12):1129–1136
44. Haynes AG, Wertli MM, Aujesky D (2020) Automated delineation
Osteoporos Int
of hospital service areas as a new tool for health care planning.
Health Serv Res 55(3):469–475
45. Wennberg J, Gittelsohn A (1973) Small area variations in health
care delivery. Science. 182(4117):1102–1108
Publisher’s note Springer Nature remains neutral with regard to jurisdic-
tional claims in published maps and institutional affiliations.
Osteoporos Int
